Multiple Sclerosis
Conference Coverage
Evobrutinib demonstrates efficacy, safety in relapsing MS
PHILADELPHIA – Primary endpoint of reducing enhancing lesions versus placebo was met with evobrutinib.
Conference Coverage
Fingolimod reduced disease activity more than glatiramer acetate in RRMS: ASSESS study results
PHILADELPHIA – Relapse rate and radiographic endpoints significantly improved with the 0.5-mg daily dose of fingolimod, with safety as expected...
Conference Coverage
Ocrelizumab effective, safe in relapsing-remitting MS patients
PHILADELPHIA - A positive risk-to-benefit ratio over nearly 1 year for the anti-CD20 monoclonal antibody.
Conference Coverage
Sugary drink intake may be associated with MS severity
PHILADELPHIA – Among patients with multiple sclerosis, consumption of sugar-sweetened beverages may be associated with more severe disability,...
From the Journals
BTK inhibitor reduces MS enhancing lesions
However, neither the 75-mg nor 25-mg dosing regimens significantly reduced Expanded Disability Status Scale scores, compared with placebo.
Conference Coverage
Changes in brain networks may predict MS worsening
PHILADELPHIA – Structural and functional network MRI measures appear to identify patients at high risk for increased...
Conference Coverage
Ibudilast’s efficacy differs in primary and secondary progressive MS
PHILADELPHIA – Efficacy in a phase 2 trial was driven by patients with primary progressive MS, which may be related to faster brain atrophy rates...
Conference Coverage
The art of selecting an MS therapy
DALLAS – Clinical and imaging findings may indicate disease phase, severity, and prognosis, which can inform the treatment choice.
Conference Coverage
Researchers examine vitamin D, skin pigmentation, and outcomes of pediatric MS
PHILADELPHIA – The association between vitamin D insufficiency and MS outcome in children appears to relate partly...
Latest News
Criterion based on the central vein sign distinguishes between MS and mimics
PHILADELPHIA – Applying the criterion of three lesions with the central vein sign is feasible in clinical practice...
Conference Coverage
Eculizumab cuts relapse risk in NMO spectrum disorder
PHILADELPHIA – Nearly 98% of patients with this autoimmune inflammatory CNS disorder were relapse-free at 48 weeks in the randomized phase 3...